(a)
(b)
Figure 6: The ERK kinase inhibitor suppressed ebastine-induced cell growth of HFDPC. HFDPC were plated in triplicate in 24-well plates for 24 h. The cells were serum starved for 18 h and then treated with the indicated concentrations of ebastine in the presence or absence of the AKT1/2 kinase inhibitor (5 μM) or PD98059 (50 μM) for 24-48 h. Cell viability (a) and proliferation (b) were analyzed by WST-1 and bromodeoxyuridine (BrdU) assays, respectively. Representative results of three independent experiments are shown and are presented as the mean ± SD after being normalized to the control group. indicates p< 0.05.